APA (7th ed.) Citation

V, V., P, R., YH, K., D, C., AT, N., & SV, L. (2024). 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC. Clinical lung cancer, 25(6), 502. https://doi.org/10.1016/j.cllc.2024.05.002

Chicago Style (17th ed.) Citation

V, Velcheti, Rai P, Kao YH, Chirovsky D, Nunes AT, and Liu SV. "5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC." Clinical Lung Cancer 25, no. 6 (2024): 502. https://doi.org/10.1016/j.cllc.2024.05.002.

MLA (9th ed.) Citation

V, Velcheti, et al. "5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC." Clinical Lung Cancer, vol. 25, no. 6, 2024, p. 502, https://doi.org/10.1016/j.cllc.2024.05.002.